Anti-inflammatory effects of intravenous methotrexate associated with lipid nanoemulsions on antigen-induced arthritis

Suzana B V Mello, Elaine R Tavares, Maria Carolina Guido, Eloisa Bonfá, Raul C Maranhão, Suzana B V Mello, Elaine R Tavares, Maria Carolina Guido, Eloisa Bonfá, Raul C Maranhão

Abstract

Objective: To test the hypothesis that intravenous use of methotrexate associated with lipid nanoemulsions can achieve superior anti-inflammatory effects in the joints of rabbits with antigen-induced arthritis compared with commercial methotrexate.

Methods: Arthritis was induced in New Zealand rabbits sensitized with methylated bovine serum albumin and subsequently intra-articularly injected with the antigen. A nanoemulsion of methotrexate labeled with 3H-cholesteryl ether (4 mg/kg methotrexate) was then intravenously injected into four rabbits to determine the plasma decaying curves and the biodistribution of the methotrexate nanoemulsion by radioactive counting. Additionally, the pharmacokinetics of the methotrexate nanoemulsion were determined by high-pressure liquid chromatography. Twenty-four hours after arthritis induction, the animals were allocated into three groups, with intravenous injection with saline solution (n=9), methotrexate nanoemulsion (0.5 µmol/kg methotrexate, n=7), or commercial methotrexate (0.5 µmol/kg, n=4). The rabbits were sacrificed 24 h afterward. Synovial fluid was then collected for protein leakage and cell content analyses and synovial membranes were collected for histopathological analysis.

Results: The methotrexate nanoemulsion was taken up mainly by the liver and the uptake by arthritic joints was two-fold greater than that by control joints. The methotrexate nanoemulsion treatment reduced leukocyte influx into the synovial fluid by nearly 65%; in particular, mononuclear and polymorphonuclear cells were reduced by 47 and 72%, respectively. In contrast, cell influx was unaffected following treatment with commercial methotrexate. Protein leakage into the arthritic knees of the rabbits was also more limited following methotrexate nanoemulsion treatment than following commercial methotrexate treatment.

Conclusions: The intravenous methotrexate nanoemulsion showed anti-inflammatory effects on the synovia of arthritic joints that were clearly superior to the effects of a commercial methotrexate preparation. This result is conceivably due to greater methotrexate uptake by the joints when the drug is associated with a nanoemulsion.

Conflict of interest statement

No potential conflict of interest was reported.

Figures

Figure 1-
Figure 1-
Decay curve of didodecyl MTX associated with an LDE after a bolus injection of 3.6 mg/kg drug and pharmacokinetic parameters obtained from the curve. The concentration of MTX in the plasma was determined by HPLC. The analysis was performed using a two-compartment open model. t1/2β: elimination half-life; AUC: area under the plasma concentration-time curve; Vss: volume of distribution at steady state; CL: total body clearance. The results are expressed as the mean ± SE of data obtained from 4 rabbits.
Figure 2-
Figure 2-
Tissue uptake of LDE labeled with 3H-cholesteryl oleyl ether. The tissue samples were excised for radioactivity counting 24 h after intravenous injection of the labeled LDE into the rabbits with AIA. Contralateral synovia without arthritis induction were used as controls.
Figure 3-
Figure 3-
Leukocyte count (monocytes: white column; polymorphonuclear cells: gray column) in the synovial fluid of rabbits 48 h after AIA induction. The animals received commercial MTX (0.5 µmol/kg), LDE-MTX (0.5 µmol/kg) or saline solution intravenously 24 h after AIA induction. * p<0.05 compared with the control saline-treated rabbits with AIA. The results are expressed as the mean ± SEM. The data have been subjected to repeated analysis of variance. Post-analysis was conducted using Newman-Keuls multiple comparison tests. In all analyses, p<0.05 was considered statistically significant.
Figure 4-
Figure 4-
Vascular permeability, as assessed by the Evans Blue method, in joint fluid collected from the joints of rabbits 48 h after AIA induction. The animals received intravenous commercial MTX (0.5 µmol/kg), LDE-MTX (0.5 µmol/kg) or saline solution 24 h after the induction of arthritis. *p<0.05 compared with the control saline-treated rabbits with AIA. The results are expressed as the mean ± SEM. The data have been subjected to repeated analysis of variance. Post-analysis was conducted using Newman-Keuls multiple comparison tests. In all analyses, p<0.05 was considered statistically significant.

References

    1. Mello SB, Tavares ER, Bulgarelli A, Bonfá E, Maranhão RC. Intra-articular methotrexate associated to lipid nanoemulsions: anti-inflammatory effect upon antigen-induced arthritis. Int J Nanomedicine. 2013;8:443–9.
    1. Maranhão RC, Cesar TB, Pedroso-Mariani SR, Hirata MH, Mesquita CH. Metabolic behavior in rats of a nonprotein microemulsion resembling low-density lipoprotein. Lipids. 1993;28((8)):691–6.
    1. Maranhão RC, Roland IA, Toffoletto O, Ramires JA, Gonçalves RP, Mesquita CH, et al. Plasma kinetic behavior in hyperlipidemic subjects of a lipidic microemulsion that binds to low density lipoprotein receptors. Lipids. 1997;32((6)):627–33.
    1. Kretzer IF, Maria DA, Maranhão RC. Drug-targeting in combined cancer chemotherapy: tumor growth inhibition in mice by association of paclitaxel and etoposide with a cholesterol-rich nanoemulsion. Cell Oncol (Dordr) 2012;35((6)):451–60.
    1. Rodrigues DG, Maria DA, Fernandes DC, Valduga CJ, Couto RD, Ibanez OC, et al. Improvement of paclitaxel therapeutic index by derivatization and association to a cholesterol-rich microemulsion: in vitro and in vivo studies. Cancer Chemother Pharmacol. 2005;55((6)):565–76.
    1. Valduga CJ, Fernandes DC, Lo Prete AC, Azevedo CH, Rodrigues DG, Maranhão RC. Use of a cholesterol-rich microemulsion that binds to low-density lipoprotein receptors as vehicle for etoposide. J Pharm Pharmacol. 2003;55((12)):1615–22.
    1. Pinheiro KV, Hungria VT, Ficker ES, Valduga CJ, Mesquita CH, Maranhão RC. Plasma&nbsp;kinetics&nbsp;of a cholesterol-rich microemulsion (LDE) in patients with Hodgkin&apos;s and non-Hodgkin&apos;s lymphoma and a preliminary study on the toxicity of etoposide associated with LDE. Cancer Chemother Pharmacol. 2006;57((5)):624–30.
    1. Pires LA, Hegg R, Valduga CJ, Graziani SR, Rodrigues DG, Maranhão RC. Use of cholesterol-rich nanoparticles that bind to lipoprotein receptors as a vehicle to paclitaxel in the treatment of breast&nbsp;cancer: pharmacokinetics, tumor uptake and a pilot clinical study. Cancer Chemother Pharmacol. 2009;63((2)):281–7.
    1. Dias ML, Carvalho JP, Rodrigues DG, Graziani SR, Maranhão RC. Pharmacokinetics and tumor uptake of a derivatized form of paclitaxel associated to a cholesterol-rich nanoemulsion (LDE) in&nbsp;patients&nbsp;with gynecologic cancers. Cancer Chemother Pharmacol. 2007;59((1)):105–11.
    1. Teixeira RS, Curi R, Maranhão RC. Effects on Walker 256 tumour of carmustine associated with a cholesterol-rich microemulsion (LDE) J Pharm Pharmacol. 2004;56((7)):909–14.
    1. Maranhão RC, Graziani SR, Yamaguchi N, Melo RF, Latrilha MC, Rodrigues DG, et al. Association of carmustine with a lipid emulsion: in vitro, in vivo and preliminary studies in cancer patients. Cancer Chemother Pharmacol. 2002;49((6)):487–98.
    1. Moura JA, Valduga CJ, Tavares ER, Kretzer IF, Maria DA, Maranhão RC. Novel formulation of a methotrexate derivative with a lipid nanoemulsion. Int J Nanomedicine. 2011;6:2285–95.
    1. Folch J, Lees M, Sloane Stanley GH. A simple method for the isolation and purification of total lipids from animal tissues. J Biol Chem. 1957;226((1)):497–509.
    1. Wong PT, Choi SK. Mechanisms and implications of dual-acting methotrexate in folate-targeted nanotherapeutic delivery. Int J Mol Sci. 2015;13;16((1)):1772–90.
    1. Abolmaali SS, Tamaddon AM, Dinarvand R. A review of therapeutic challenges and achievements of methotrexate delivery systems for treatment of cancer and rheumatoid arthritis. Cancer Chemother Pharmacol. 2013;71((5)):1115–30.
    1. Bulgarelli A, Leite AC, Jr, Dias AA, Maranhão RC. Anti-atherogenic effects of&nbsp;methotrexate&nbsp;carried by a lipid nanoemulsion that binds to LDL receptors in cholesterol-fed rabbits. Cardiovasc Drugs Ther. 2013;27((6)):531–9.

Source: PubMed

3
Prenumerera